Molecular Weight:   | 523.27 |
Volume:   | 531.998 |
LogP:   | 5.045 |
LogD:   | 3.639 |
LogS:   | -3.878 |
# Rotatable Bonds:   | 7 |
TPSA:   | 126.68 |
# H-Bond Aceptor:   | 9 |
# H-Bond Donor:   | 3 |
# Rings:   | 5 |
# Heavy Atoms:   | 9 |
QED Drug-Likeness Score:   | 0.345 |
Synthetic Accessibility Score:   | 5.357 |
Fsp3:   | 0.552 |
Lipinski Rule-of-5:   | Rejected |
Pfizer Rule:   | Accepted |
GSK Rule:   | Rejected |
BMS Rule:   | 0 |
Golden Triangle Rule:   | Rejected |
Chelating Alert:   | 0 |
PAINS Alert:   | 0 |
Caco-2 Permeability:   | -5.385 |
MDCK Permeability:   | 7.750256372673903e-06 |
Pgp-inhibitor:   | 0.016 |
Pgp-substrate:   | 0.127 |
Human Intestinal Absorption (HIA):   | 0.005 |
20% Bioavailability (F20%):   | 0.007 |
30% Bioavailability (F30%):   | 0.96 |
Blood-Brain-Barrier Penetration (BBB):   | 0.026 |
Plasma Protein Binding (PPB):   | 100.17858123779297% |
Volume Distribution (VD):   | 2.471 |
Pgp-substrate:   | 3.096024990081787% |
CYP1A2-inhibitor:   | 0.047 |
CYP1A2-substrate:   | 0.948 |
CYP2C19-inhibitor:   | 0.118 |
CYP2C19-substrate:   | 0.126 |
CYP2C9-inhibitor:   | 0.769 |
CYP2C9-substrate:   | 0.094 |
CYP2D6-inhibitor:   | 0.009 |
CYP2D6-substrate:   | 0.148 |
CYP3A4-inhibitor:   | 0.433 |
CYP3A4-substrate:   | 0.24 |
Clearance (CL):   | 5.12 |
Half-life (T1/2):   | 0.296 |
hERG Blockers:   | 0.663 |
Human Hepatotoxicity (H-HT):   | 0.953 |
Drug-inuced Liver Injury (DILI):   | 0.988 |
AMES Toxicity:   | 0.012 |
Rat Oral Acute Toxicity:   | 0.798 |
Maximum Recommended Daily Dose:   | 0.17 |
Skin Sensitization:   | 0.087 |
Carcinogencity:   | 0.219 |
Eye Corrosion:   | 0.003 |
Eye Irritation:   | 0.012 |
Respiratory Toxicity:   | 0.954 |
Natural Product ID:   | NPC196449 |
Common Name*:   | Calcimycin |
IUPAC Name:   | 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid |
Synonyms:   | Calcimycin |
Standard InCHIKey:   | HIYAVKIYRIFSCZ-CYEMHPAKSA-N |
Standard InCHI:   | InChI=1S/C29H37N3O6/c1-15-10-11-29(17(3)13-16(2)27(38-29)18(4)26(33)20-7-6-12-31-20)37-22(15)14-23-32-25-21(36-23)9-8-19(30-5)24(25)28(34)35/h6-9,12,15-18,22,27,30-31H,10-11,13-14H2,1-5H3,(H,34,35)/t15-,16-,17-,18-,22-,27+,29+/m1/s1 |
SMILES:   | C[C@@H]1CC[C@]2([C@H](C)C[C@@H](C)[C@@H]([C@H](C)C(=O)c3ccc[nH]3)O2)O[C@@H]1Cc1nc2c(ccc(c2C(=O)O)NC)o1 |
Synthetic Gene Cluster:   | n.a. |
ChEMBL Identifier:   | CHEMBL1256686 |
PubChem CID:   |
11957499 |
Chemical Classification**:   |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO8874 | Glehnia littoralis | Species | Apiaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[24813739] |
NPO40670 | Streptomyces sp. CP26-58 | Strain | Streptomycetaceae | Bacteria | n.a. | n.a. | n.a. |
PMID[28128950] |
NPO8874 | Glehnia littoralis | Species | Apiaceae | Eukaryota | n.a. | n.a. | n.a. | Database[HerDing] |
NPO8874 | Glehnia littoralis | Species | Apiaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO8874 | Glehnia littoralis | Species | Apiaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCM_Taiwan] |
NPO8874 | Glehnia littoralis | Species | Apiaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TM-MC] |
NPO8874 | Glehnia littoralis | Species | Apiaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO4212 | Acia weinmanni | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Database[UNPD] |
NPO6069 | Leontice thalictroides | Species | Berberidaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO7950 | Cortinellus shiitake | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
---|
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT1416 | Individual Protein | Neuropeptide S receptor | Homo sapiens | Potency | = | 15.8 | nM | PMID[548461] |
NPT1416 | Individual Protein | Neuropeptide S receptor | Homo sapiens | Potency | = | 10000.0 | nM | PMID[548461] |
NPT483 | Individual Protein | Prelamin-A/C | Homo sapiens | Potency | = | 3162.3 | nM | PMID[548462] |
NPT47 | Individual Protein | ATP-dependent DNA helicase Q1 | Homo sapiens | Potency | = | 35481.3 | nM | PMID[548461] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 11220.2 | nM | PMID[548462] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 12589.3 | nM | PMID[548461] |
NPT1197 | Individual Protein | Huntingtin | Homo sapiens | Potency | = | 891.3 | nM | PMID[548461] |
NPT537 | Individual Protein | Ras-related protein Rab-9A | Homo sapiens | Potency | = | 58047.9 | nM | PMID[548463] |
NPT537 | Individual Protein | Ras-related protein Rab-9A | Homo sapiens | Potency | = | 3981.1 | nM | PMID[548461] |
NPT442 | Individual Protein | Ferritin light chain | Equus caballus | Potency | = | 35481.3 | nM | PMID[548462] |
NPT1416 | Individual Protein | Neuropeptide S receptor | Homo sapiens | Potency | = | 501.2 | nM | PMID[548462] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | = | 6309.6 | nM | PMID[548462] |
NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 22387.2 | nM | PMID[548462] |
NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 31622.8 | nM | PMID[548462] |
NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 15848.9 | nM | PMID[548461] |
NPT531 | Individual Protein | Nuclear receptor ROR-gamma | Mus musculus | Potency | = | 1258.9 | nM | PMID[548461] |
NPT483 | Individual Protein | Prelamin-A/C | Homo sapiens | Potency | = | 2818.4 | nM | PMID[548462] |
NPT54 | Individual Protein | Nonstructural protein 1 | Influenza A virus | Potency | = | 19952.6 | nM | PMID[548461] |
NPT54 | Individual Protein | Nonstructural protein 1 | Influenza A virus | Potency | = | 8912.5 | nM | PMID[548462] |
NPT55 | Individual Protein | Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | = | 17740.7 | nM | PMID[548461] |
NPT538 | Individual Protein | Niemann-Pick C1 protein | Homo sapiens | Potency | = | 1122.0 | nM | PMID[548461] |
NPT4358 | Individual Protein | Type-1 angiotensin II receptor | Homo sapiens | IC50 | > | 40000.0 | nM | PMID[548461] |
NPT282 | Individual Protein | MAP kinase ERK2 | Homo sapiens | Potency | = | 39810.7 | nM | PMID[548462] |
NPT282 | Individual Protein | MAP kinase ERK2 | Homo sapiens | Potency | = | 14125.4 | nM | PMID[548461] |
NPT538 | Individual Protein | Niemann-Pick C1 protein | Homo sapiens | Potency | = | 290928.6 | nM | PMID[548463] |
NPT58 | Individual Protein | Bloom syndrome protein | Homo sapiens | Potency | = | 15848.9 | nM | PMID[548462] |
NPT151 | Individual Protein | 15-hydroxyprostaglandin dehydrogenase [NAD+] | Homo sapiens | Potency | = | 28183.8 | nM | PMID[548462] |
NPT524 | Individual Protein | Serine-protein kinase ATM | Homo sapiens | Potency | = | 39810.7 | nM | PMID[548461] |
NPT60 | Individual Protein | Lysosomal alpha-glucosidase | Homo sapiens | Potency | = | 35481.3 | nM | PMID[548461] |
NPT1416 | Individual Protein | Neuropeptide S receptor | Homo sapiens | Potency | = | 7943.3 | nM | PMID[548462] |
NPT1416 | Individual Protein | Neuropeptide S receptor | Homo sapiens | Potency | = | 1258.9 | nM | PMID[548461] |
NPT1254 | Individual Protein | Streptokinase A | Streptococcus pyogenes serotype M1 | EC50 | < | 60.0 | nM | PMID[548461] |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | = | 1584.9 | nM | PMID[548462] |
NPT61 | Individual Protein | Beta-glucocerebrosidase | Homo sapiens | Potency | n.a. | 35481.3 | nM | PMID[548462] |
NPT64 | Individual Protein | ATPase family AAA domain-containing protein 5 | Homo sapiens | Potency | n.a. | 29081.0 | nM | PMID[548463] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 4109.5 | nM | PMID[548463] |
NPT532 | Individual Protein | Lysine-specific demethylase 4A | Homo sapiens | Potency | n.a. | 12589.3 | nM | PMID[548461] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 1158.2 | nM | PMID[548461] |
NPT242 | Individual Protein | Dopamine D1 receptor | Homo sapiens | Potency | n.a. | 354.8 | nM | PMID[548463] |
NPT2892 | Individual Protein | X-box-binding protein 1 | Homo sapiens | IC50 | = | 1410.0 | nM | PMID[548461] |
NPT443 | Individual Protein | Histone acetyltransferase GCN5 | Homo sapiens | Potency | n.a. | 19952.6 | nM | PMID[548463] |
NPT62 | Individual Protein | 6-phospho-1-fructokinase | Trypanosoma brucei | Potency | n.a. | 23.9 | nM | PMID[548463] |
NPT135 | Individual Protein | Chromobox protein homolog 1 | Homo sapiens | Potency | n.a. | 6.0 | nM | PMID[548463] |
NPT2893 | Individual Protein | DNA damage-inducible transcript 3 protein | Mus musculus | IC50 | = | 160.0 | nM | PMID[548461] |
NPT64 | Individual Protein | ATPase family AAA domain-containing protein 5 | Homo sapiens | Potency | n.a. | 5802.4 | nM | PMID[548461] |
NPT64 | Individual Protein | ATPase family AAA domain-containing protein 5 | Homo sapiens | Potency | n.a. | 12990.0 | nM | PMID[548463] |
NPT242 | Individual Protein | Dopamine D1 receptor | Homo sapiens | Potency | n.a. | 398.1 | nM | PMID[548463] |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | n.a. | 19011.5 | nM | PMID[548462] |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | n.a. | 29092.9 | nM | PMID[548462] |
NPT198 | Individual Protein | Vitamin D receptor | Homo sapiens | Potency | n.a. | 44668.4 | nM | PMID[548463] |
NPT478 | Individual Protein | Ataxin-2 | Homo sapiens | Potency | n.a. | 3162.3 | nM | PMID[548463] |
NPT1397 | Cell Line | INS1 | Rattus norvegicus | AC50 | = | 2078.0 | nM | PMID[548461] |
NPT444 | Individual Protein | Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens | Potency | n.a. | 46945.0 | nM | PMID[548463] |
NPT65 | Cell Line | HepG2 | Homo sapiens | Potency | n.a. | 7079.5 | nM | PMID[548461] |
NPT5114 | Individual Protein | Beta-galactosidase | Escherichia coli | EC50 | > | 40000.0 | nM | PMID[548461] |
NPT154 | Individual Protein | Mothers against decapentaplegic homolog 3 | Homo sapiens | Potency | n.a. | 5011.9 | nM | PMID[548461] |
NPT71 | Cell Line | HEK293 | Homo sapiens | Potency | n.a. | 7079.5 | nM | PMID[548462] |
NPT71 | Cell Line | HEK293 | Homo sapiens | Potency | n.a. | 231.0 | nM | PMID[548463] |
NPT519 | Cell Line | SH-SY5Y | Homo sapiens | Potency | n.a. | 3162.3 | nM | PMID[548463] |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | n.a. | 23934.1 | nM | PMID[548461] |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | n.a. | 7568.6 | nM | PMID[548463] |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | n.a. | 3013.1 | nM | PMID[548461] |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | n.a. | 4610.9 | nM | PMID[548461] |
NPT100 | Individual Protein | Glutaminase kidney isoform, mitochondrial | Homo sapiens | Potency | n.a. | 15848.9 | nM | PMID[548461] |
NPT156 | Individual Protein | Sphingomyelin phosphodiesterase | Homo sapiens | Potency | n.a. | 25118.9 | nM | PMID[548461] |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | n.a. | 8912.5 | nM | PMID[548461] |
NPT478 | Individual Protein | Ataxin-2 | Homo sapiens | Potency | n.a. | 3548.1 | nM | PMID[548463] |
NPT478 | Individual Protein | Ataxin-2 | Homo sapiens | Potency | n.a. | 7079.5 | nM | PMID[548461] |
NPT101 | Individual Protein | Glucagon-like peptide 1 receptor | Homo sapiens | Potency | n.a. | 2238.7 | nM | PMID[548461] |
NPT159 | Individual Protein | Aberrant vpr protein | Human immunodeficiency virus 1 | Potency | n.a. | 12589.3 | nM | PMID[548461] |
NPT66 | Individual Protein | Acetylcholinesterase | Electrophorus electricus | Inhibition | = | -15.43 | % | PMID[548465] |
NPT5115 | Individual Protein | Ryanodien receptor | Spodoptera exigua | Activity | = | 357.5 | % | PMID[548466] |
NPT5115 | Individual Protein | Ryanodien receptor | Spodoptera exigua | Activity | = | 157.9 | % | PMID[548466] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 183.6 | nM | PMID[548461] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 25.9 | nM | PMID[548461] |
NPT160 | Individual Protein | TAR DNA-binding protein 43 | Homo sapiens | Potency | n.a. | 10000.0 | nM | PMID[548461] |
NPT2552 | Individual Protein | Calcium-activated potassium channel subunit alpha-1 | Homo sapiens | Activity | = | 416.0 | % | PMID[548467] |
NPT154 | Individual Protein | Mothers against decapentaplegic homolog 3 | Homo sapiens | Potency | n.a. | 1032.3 | nM | PMID[548461] |
NPT446 | Individual Protein | Rap guanine nucleotide exchange factor 3 | Homo sapiens | Potency | n.a. | 14125.4 | nM | PMID[548461] |
NPT535 | Individual Protein | Parathyroid hormone receptor | Homo sapiens | Potency | n.a. | 28183.8 | nM | PMID[548461] |
NPT154 | Individual Protein | Mothers against decapentaplegic homolog 3 | Homo sapiens | Potency | n.a. | 2059.6 | nM | PMID[548461] |
NPT104 | Individual Protein | Cerebroside-sulfatase | Homo sapiens | Potency | n.a. | 8492.1 | nM | PMID[548463] |
NPT154 | Individual Protein | Mothers against decapentaplegic homolog 3 | Homo sapiens | Potency | n.a. | 6513.1 | nM | PMID[548461] |
NPT11 | Individual Protein | Guanine nucleotide-binding protein G(s), subunit alpha | Homo sapiens | Potency | n.a. | 7943.3 | nM | PMID[548461] |
NPT446 | Individual Protein | Rap guanine nucleotide exchange factor 3 | Homo sapiens | Potency | n.a. | 79432.8 | nM | PMID[548461] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | IC50 | = | 1.0 | nM | PMID[548460] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | IC50 | = | 1.05 | nM | PMID[548460] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | IC50 | = | 1.32 | nM | PMID[548460] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | IC50 | = | 1.41 | nM | PMID[548460] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | IC50 | = | 1000.0 | nM | PMID[548460] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | IC50 | = | 1258.93 | nM | PMID[548460] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | = | 1412.5 | nM | PMID[548462] |
NPT174 | Organism | Streptococcus | Streptococcus | EC50 | = | 128.0 | nM | PMID[548461] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | = | 1000.0 | nM | PMID[548462] |
NPT2 | Others | Unspecified | EC50 | = | 293.0 | nM | PMID[548461] | |
NPT1252 | Organism | Streptococcus sp. 'group A' | Streptococcus sp. 'group A' | EC50 | < | 60.0 | nM | PMID[548461] |
NPT2 | Others | Unspecified | Potency | = | 1258.9 | nM | PMID[548462] | |
NPT312 | Organism | Saccharomyces cerevisiae | Saccharomyces cerevisiae | Potency | = | 18356.4 | nM | PMID[548463] |
NPT536 | Uncleic Acid | microRNA 21 | Homo sapiens | Potency | = | 7362.1 | nM | PMID[548461] |
NPT93 | Individual Protein | Survival motor neuron protein | Homo sapiens | Potency | = | 8912.5 | nM | PMID[548462] |
NPT2 | Others | Unspecified | IC50 | = | 1100.0 | nM | PMID[548461] | |
NPT940 | Individual Protein | Serine/threonine-protein kinase mTOR | Homo sapiens | Potency | = | 1468.9 | nM | PMID[548463] |
NPT2 | Others | Unspecified | Potency | = | 4466.8 | nM | PMID[548462] | |
NPT2 | Others | Unspecified | Potency | = | 7079.5 | nM | PMID[548462] | |
NPT791 | Individual Protein | Cruzipain | Trypanosoma cruzi | Potency | = | 39810.7 | nM | PMID[548462] |
NPT794 | Individual Protein | Endonuclease 4 | Escherichia coli K-12 | Potency | = | 3981.1 | nM | PMID[548462] |
NPT94 | Individual Protein | Aldehyde dehydrogenase 1A1 | Homo sapiens | Potency | = | 19952.6 | nM | PMID[548462] |
NPT2 | Others | Unspecified | Potency | = | 259.3 | nM | PMID[548461] | |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | = | 1258.9 | nM | PMID[548462] |
NPT796 | Individual Protein | Peripheral myelin protein 22 | Homo sapiens | Potency | = | 6012.0 | nM | PMID[548462] |
NPT940 | Individual Protein | Serine/threonine-protein kinase mTOR | Homo sapiens | Potency | = | 2612.2 | nM | PMID[548463] |
NPT2 | Others | Unspecified | CC50 | = | 319.0 | nM | PMID[548461] | |
NPT940 | Individual Protein | Serine/threonine-protein kinase mTOR | Homo sapiens | Potency | = | 2328.1 | nM | PMID[548463] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | = | 1122.0 | nM | PMID[548462] |
NPT2 | Others | Unspecified | IC50 | = | 2820.0 | nM | PMID[548461] | |
NPT940 | Individual Protein | Serine/threonine-protein kinase mTOR | Homo sapiens | Potency | = | 14689.2 | nM | PMID[548463] |
NPT2 | Others | Unspecified | EC50 | = | 172.0 | nM | PMID[548461] | |
NPT2 | Others | Unspecified | EC50 | = | 267.0 | nM | PMID[548461] | |
NPT602 | Organism | Mycobacterium smegmatis | Mycobacterium smegmatis | MIC | = | 12500.0 | nM | PMID[548464] |
NPT602 | Organism | Mycobacterium smegmatis | Mycobacterium smegmatis | IC50 | = | 5210.0 | nM | PMID[548464] |
NPT602 | Organism | Mycobacterium smegmatis | Mycobacterium smegmatis | IC50 | = | 1040.0 | nM | PMID[548464] |
NPT602 | Organism | Mycobacterium smegmatis | Mycobacterium smegmatis | MIC | = | 3125.0 | nM | PMID[548464] |
NPT602 | Organism | Mycobacterium smegmatis | Mycobacterium smegmatis | IC50 | = | 3430.0 | nM | PMID[548464] |
NPT2 | Others | Unspecified | Potency | n.a. | 3662.6 | nM | PMID[548461] | |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | n.a. | 37685.8 | nM | PMID[548463] |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | n.a. | 21192.3 | nM | PMID[548463] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 104.2 | nM | PMID[548462] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 2332.3 | nM | PMID[548462] |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | n.a. | 39810.7 | nM | PMID[548461] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 414.7 | nM | PMID[548461] |
NPT23263 | SINGLE PROTEIN | HSP40, subfamily A, putative | Plasmodium falciparum 3D7 | AbsAC1000_uM | = | 0.662 | uM | PMID[548461] |
NPT888 | Individual Protein | 78 kDa glucose-regulated protein | Homo sapiens | Potency | n.a. | 2930.9 | nM | PMID[548463] |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | n.a. | 1000.0 | nM | PMID[548463] |
NPT803 | Individual Protein | Flap endonuclease 1 | Homo sapiens | Potency | n.a. | 2993.5 | nM | PMID[548463] |
NPT8 | Individual Protein | DNA polymerase iota | Homo sapiens | Potency | n.a. | 50118.7 | nM | PMID[548461] |
NPT98 | Individual Protein | HERG | Homo sapiens | Potency | n.a. | 3162.3 | nM | PMID[548462] |
NPT698 | Individual Protein | Regulator of G-protein signaling 4 | Homo sapiens | Potency | n.a. | 26679.5 | nM | PMID[548463] |
NPT2 | Others | Unspecified | Potency | n.a. | 1122.0 | nM | PMID[548461] | |
NPT698 | Individual Protein | Regulator of G-protein signaling 4 | Homo sapiens | Potency | n.a. | 100000.0 | nM | PMID[548461] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 928.5 | nM | PMID[548461] |
NPT2 | Others | Unspecified | Potency | n.a. | 2908.1 | nM | PMID[548463] | |
NPT918 | Individual Protein | Heat shock protein HSP 90-alpha | Homo sapiens | AC50 | = | 1074.0 | nM | PMID[548461] |
NPT2 | Others | Unspecified | Potency | n.a. | 707.9 | nM | PMID[548462] | |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | n.a. | 25118.9 | nM | PMID[548463] |
NPT919 | Individual Protein | HSP90 | Plasmodium falciparum 3D7 | AC50 | = | 813.0 | nM | PMID[548461] |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | n.a. | 22387.2 | nM | PMID[548461] |
NPT888 | Individual Protein | 78 kDa glucose-regulated protein | Homo sapiens | Potency | n.a. | 464.5 | nM | PMID[548463] |
NPT2 | Others | Unspecified | Potency | n.a. | 5011.9 | nM | PMID[548461] | |
NPT2 | Others | Unspecified | AbsAC35_uM | n.a. | 11.07 | uM | PMID[548461] | |
NPT2 | Others | Unspecified | Potency | n.a. | 2238.7 | nM | PMID[548461] | |
NPT67 | Individual Protein | Cholinesterase | Equus caballus | Inhibition | = | -3.34 | % | PMID[548465] |
NPT2 | Others | Unspecified | Potency | n.a. | 2059.6 | nM | PMID[548461] | |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | AbsAC35 | = | 0.833 | uM | PMID[548461] |
NPT861 | Individual Protein | Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens | Potency | n.a. | 1458.1 | nM | PMID[548461] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | AbsAC35 | = | 1.01 | uM | PMID[548461] |
NPT920 | Individual Protein | Alpha-synuclein | Homo sapiens | Potency | n.a. | 6513.1 | nM | PMID[548463] |
NPT2 | Others | Unspecified | Potency | n.a. | 27282.4 | nM | PMID[548463] | |
NPT2 | Others | Unspecified | Potency | n.a. | 3548.1 | nM | PMID[548461] | |
NPT2 | Others | Unspecified | Potency | n.a. | 1458.1 | nM | PMID[548461] | |
NPT2 | Others | Unspecified | Potency | n.a. | 3981.1 | nM | PMID[548461] | |
NPT78 | Individual Protein | Beta amyloid A4 protein | Homo sapiens | Potency | n.a. | 1458.1 | nM | PMID[548463] |
NPT831 | Individual Protein | Serine/threonine-protein kinase PLK1 | Homo sapiens | Potency | n.a. | 18887.6 | nM | PMID[548461] |
NPT2 | Others | Unspecified | Potency | n.a. | 2511.9 | nM | PMID[548461] | |
NPT2 | Others | Unspecified | Potency | n.a. | 29092.9 | nM | PMID[548463] | |
NPT2 | Others | Unspecified | Potency | n.a. | 2818.4 | nM | PMID[548463] | |
NPT2 | Others | Unspecified | Potency | n.a. | 2348.5 | nM | PMID[548463] | |
NPT2 | Others | Unspecified | Potency | n.a. | 12589.3 | nM | PMID[548461] |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC196449 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC314222 |
0.8294 | Intermediate Similarity | NPC161801 |
0.8105 | Intermediate Similarity | NPC196718 |
0.8105 | Intermediate Similarity | NPC102593 |
0.7795 | Intermediate Similarity | NPC53534 |
0.7753 | Intermediate Similarity | NPC152620 |
0.7743 | Intermediate Similarity | NPC148889 |
0.7632 | Intermediate Similarity | NPC258048 |
0.7626 | Intermediate Similarity | NPC15801 |
0.7549 | Intermediate Similarity | NPC182222 |
0.7537 | Intermediate Similarity | NPC472436 |
0.7481 | Intermediate Similarity | NPC316224 |
0.747 | Intermediate Similarity | NPC314633 |
0.745 | Intermediate Similarity | NPC74360 |
0.7425 | Intermediate Similarity | NPC472435 |
0.7423 | Intermediate Similarity | NPC240384 |
0.7406 | Intermediate Similarity | NPC165964 |
0.7378 | Intermediate Similarity | NPC473800 |
0.7343 | Intermediate Similarity | NPC216369 |
0.7341 | Intermediate Similarity | NPC26543 |
0.7315 | Intermediate Similarity | NPC140296 |
0.731 | Intermediate Similarity | NPC207620 |
0.7303 | Intermediate Similarity | NPC91868 |
0.7303 | Intermediate Similarity | NPC63971 |
0.7297 | Intermediate Similarity | NPC477112 |
0.7293 | Intermediate Similarity | NPC72715 |
0.7285 | Intermediate Similarity | NPC169716 |
0.7283 | Intermediate Similarity | NPC276657 |
0.7283 | Intermediate Similarity | NPC142385 |
0.7262 | Intermediate Similarity | NPC288349 |
0.7262 | Intermediate Similarity | NPC101350 |
0.7256 | Intermediate Similarity | NPC472434 |
0.7256 | Intermediate Similarity | NPC78609 |
0.7252 | Intermediate Similarity | NPC477549 |
0.7249 | Intermediate Similarity | NPC137353 |
0.7231 | Intermediate Similarity | NPC260434 |
0.7228 | Intermediate Similarity | NPC178858 |
0.7224 | Intermediate Similarity | NPC235685 |
0.7206 | Intermediate Similarity | NPC478083 |
0.7203 | Intermediate Similarity | NPC207686 |
0.7198 | Intermediate Similarity | NPC205372 |
0.719 | Intermediate Similarity | NPC473833 |
0.7175 | Intermediate Similarity | NPC173250 |
0.7171 | Intermediate Similarity | NPC212766 |
0.7171 | Intermediate Similarity | NPC289423 |
0.7169 | Intermediate Similarity | NPC478045 |
0.7154 | Intermediate Similarity | NPC208364 |
0.7154 | Intermediate Similarity | NPC153452 |
0.7149 | Intermediate Similarity | NPC321428 |
0.7149 | Intermediate Similarity | NPC193238 |
0.7148 | Intermediate Similarity | NPC39370 |
0.7138 | Intermediate Similarity | NPC328928 |
0.7137 | Intermediate Similarity | NPC184408 |
0.7137 | Intermediate Similarity | NPC131885 |
0.7137 | Intermediate Similarity | NPC473186 |
0.7127 | Intermediate Similarity | NPC208522 |
0.7121 | Intermediate Similarity | NPC90019 |
0.7116 | Intermediate Similarity | NPC72905 |
0.7109 | Intermediate Similarity | NPC288987 |
0.7109 | Intermediate Similarity | NPC269270 |
0.7107 | Intermediate Similarity | NPC101312 |
0.7106 | Intermediate Similarity | NPC475301 |
0.7106 | Intermediate Similarity | NPC326930 |
0.7105 | Intermediate Similarity | NPC475816 |
0.71 | Intermediate Similarity | NPC58209 |
0.7094 | Intermediate Similarity | NPC477589 |
0.7094 | Intermediate Similarity | NPC477587 |
0.7093 | Intermediate Similarity | NPC216612 |
0.7091 | Intermediate Similarity | NPC74619 |
0.709 | Intermediate Similarity | NPC291609 |
0.709 | Intermediate Similarity | NPC188400 |
0.7087 | Intermediate Similarity | NPC477979 |
0.7082 | Intermediate Similarity | NPC14686 |
0.7079 | Intermediate Similarity | NPC475844 |
0.7077 | Intermediate Similarity | NPC24370 |
0.7077 | Intermediate Similarity | NPC319232 |
0.7076 | Intermediate Similarity | NPC471978 |
0.7075 | Intermediate Similarity | NPC110182 |
0.7072 | Intermediate Similarity | NPC474192 |
0.7072 | Intermediate Similarity | NPC475720 |
0.7072 | Intermediate Similarity | NPC469554 |
0.7066 | Intermediate Similarity | NPC229893 |
0.7063 | Intermediate Similarity | NPC123839 |
0.7063 | Intermediate Similarity | NPC309845 |
0.7061 | Intermediate Similarity | NPC471979 |
0.7061 | Intermediate Similarity | NPC470042 |
0.7052 | Intermediate Similarity | NPC124300 |
0.705 | Intermediate Similarity | NPC478078 |
0.705 | Intermediate Similarity | NPC257851 |
0.7041 | Intermediate Similarity | NPC477586 |
0.7041 | Intermediate Similarity | NPC477590 |
0.7041 | Intermediate Similarity | NPC477588 |
0.7041 | Intermediate Similarity | NPC168922 |
0.7041 | Intermediate Similarity | NPC477585 |
0.7034 | Intermediate Similarity | NPC474688 |
0.7026 | Intermediate Similarity | NPC160100 |
0.7023 | Intermediate Similarity | NPC274640 |
0.7023 | Intermediate Similarity | NPC194740 |
0.702 | Intermediate Similarity | NPC16066 |
0.7018 | Intermediate Similarity | NPC120513 |
0.7018 | Intermediate Similarity | NPC13603 |
0.7016 | Intermediate Similarity | NPC323969 |
0.7008 | Intermediate Similarity | NPC101543 |
0.7008 | Intermediate Similarity | NPC49547 |
0.7 | Intermediate Similarity | NPC471013 |
0.7 | Intermediate Similarity | NPC180668 |
0.7 | Intermediate Similarity | NPC122436 |
0.7 | Intermediate Similarity | NPC148896 |
0.6996 | Remote Similarity | NPC67401 |
0.6992 | Remote Similarity | NPC36405 |
0.6992 | Remote Similarity | NPC57453 |
0.6989 | Remote Similarity | NPC166712 |
0.6985 | Remote Similarity | NPC186351 |
0.6984 | Remote Similarity | NPC266249 |
0.6982 | Remote Similarity | NPC53255 |
0.6982 | Remote Similarity | NPC85879 |
0.6981 | Remote Similarity | NPC323752 |
0.698 | Remote Similarity | NPC476287 |
0.698 | Remote Similarity | NPC39500 |
0.6974 | Remote Similarity | NPC310618 |
0.6973 | Remote Similarity | NPC97746 |
0.6968 | Remote Similarity | NPC478006 |
0.6966 | Remote Similarity | NPC184680 |
0.6965 | Remote Similarity | NPC472285 |
0.696 | Remote Similarity | NPC10904 |
0.6955 | Remote Similarity | NPC34770 |
0.6953 | Remote Similarity | NPC230683 |
0.6945 | Remote Similarity | NPC329982 |
0.6945 | Remote Similarity | NPC314882 |
0.6942 | Remote Similarity | NPC185197 |
0.6941 | Remote Similarity | NPC26679 |
0.6941 | Remote Similarity | NPC219087 |
0.694 | Remote Similarity | NPC470784 |
0.694 | Remote Similarity | NPC227824 |
0.694 | Remote Similarity | NPC470785 |
0.694 | Remote Similarity | NPC315467 |
0.6926 | Remote Similarity | NPC8022 |
0.6926 | Remote Similarity | NPC473639 |
0.6926 | Remote Similarity | NPC470799 |
0.692 | Remote Similarity | NPC478080 |
0.6918 | Remote Similarity | NPC282346 |
0.6917 | Remote Similarity | NPC70155 |
0.6917 | Remote Similarity | NPC171787 |
0.6914 | Remote Similarity | NPC229348 |
0.6914 | Remote Similarity | NPC317752 |
0.6911 | Remote Similarity | NPC315804 |
0.6911 | Remote Similarity | NPC313804 |
0.6906 | Remote Similarity | NPC474701 |
0.6903 | Remote Similarity | NPC184225 |
0.6898 | Remote Similarity | NPC203373 |
0.6897 | Remote Similarity | NPC144452 |
0.6894 | Remote Similarity | NPC311906 |
0.6893 | Remote Similarity | NPC209981 |
0.6887 | Remote Similarity | NPC118228 |
0.6886 | Remote Similarity | NPC1608 |
0.6885 | Remote Similarity | NPC54066 |
0.6885 | Remote Similarity | NPC472099 |
0.6884 | Remote Similarity | NPC471015 |
0.6882 | Remote Similarity | NPC191489 |
0.6875 | Remote Similarity | NPC318299 |
0.6875 | Remote Similarity | NPC118940 |
0.6873 | Remote Similarity | NPC309919 |
0.6873 | Remote Similarity | NPC473188 |
0.687 | Remote Similarity | NPC322482 |
0.6868 | Remote Similarity | NPC132385 |
0.6868 | Remote Similarity | NPC326363 |
0.6867 | Remote Similarity | NPC315499 |
0.6863 | Remote Similarity | NPC269367 |
0.6858 | Remote Similarity | NPC60621 |
0.6856 | Remote Similarity | NPC157931 |
0.6856 | Remote Similarity | NPC74575 |
0.6855 | Remote Similarity | NPC478009 |
0.6855 | Remote Similarity | NPC478010 |
0.6854 | Remote Similarity | NPC329631 |
0.6853 | Remote Similarity | NPC471303 |
0.685 | Remote Similarity | NPC475533 |
0.6846 | Remote Similarity | NPC298436 |
0.6844 | Remote Similarity | NPC314056 |
0.6844 | Remote Similarity | NPC100734 |
0.6844 | Remote Similarity | NPC88923 |
0.6844 | Remote Similarity | NPC315634 |
0.6842 | Remote Similarity | NPC217176 |
0.684 | Remote Similarity | NPC315491 |
0.684 | Remote Similarity | NPC45459 |
0.6838 | Remote Similarity | NPC75179 |
0.6836 | Remote Similarity | NPC187501 |
0.6836 | Remote Similarity | NPC82370 |
0.6834 | Remote Similarity | NPC312645 |
0.6834 | Remote Similarity | NPC27041 |
0.6828 | Remote Similarity | NPC260909 |
0.6828 | Remote Similarity | NPC325976 |
0.6827 | Remote Similarity | NPC99891 |
0.6825 | Remote Similarity | NPC324619 |
0.6825 | Remote Similarity | NPC475774 |
0.6825 | Remote Similarity | NPC475315 |
0.6824 | Remote Similarity | NPC185782 |
0.6822 | Remote Similarity | NPC478157 |
0.682 | Remote Similarity | NPC132642 |
0.6809 | Remote Similarity | NPC472098 |
0.6808 | Remote Similarity | NPC96321 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC196449 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.7937 | Intermediate Similarity | NPD3006 | Discontinued |
0.7795 | Intermediate Similarity | NPD7853 | Phase 2 |
0.7791 | Intermediate Similarity | NPD5483 | Clinical (unspecified phase) |
0.7738 | Intermediate Similarity | NPD5022 | Discontinued |
0.7621 | Intermediate Similarity | NPD4429 | Discontinued |
0.761 | Intermediate Similarity | NPD7547 | Clinical (unspecified phase) |
0.7605 | Intermediate Similarity | NPD5482 | Discontinued |
0.7433 | Intermediate Similarity | NPD2921 | Clinical (unspecified phase) |
0.739 | Intermediate Similarity | NPD8279 | Clinical (unspecified phase) |
0.7346 | Intermediate Similarity | NPD2951 | Discontinued |
0.7336 | Intermediate Similarity | NPD5450 | Discontinued |
0.7331 | Intermediate Similarity | NPD2433 | Clinical (unspecified phase) |
0.732 | Intermediate Similarity | NPD3945 | Discontinued |
0.7312 | Intermediate Similarity | NPD6974 | Phase 3 |
0.729 | Intermediate Similarity | NPD4958 | Clinical (unspecified phase) |
0.724 | Intermediate Similarity | NPD5416 | Discontinued |
0.7237 | Intermediate Similarity | NPD6247 | Clinical (unspecified phase) |
0.7224 | Intermediate Similarity | NPD4368 | Phase 2 |
0.7222 | Intermediate Similarity | NPD5293 | Phase 2 |
0.7216 | Intermediate Similarity | NPD6242 | Discontinued |
0.7212 | Intermediate Similarity | NPD6525 | Clinical (unspecified phase) |
0.7209 | Intermediate Similarity | NPD3263 | Phase 3 |
0.7209 | Intermediate Similarity | NPD7603 | Discontinued |
0.7195 | Intermediate Similarity | NPD2779 | Approved |
0.7194 | Intermediate Similarity | NPD3394 | Approved |
0.7194 | Intermediate Similarity | NPD3389 | Approved |
0.7194 | Intermediate Similarity | NPD3393 | Approved |
0.7189 | Intermediate Similarity | NPD2510 | Approved |
0.7189 | Intermediate Similarity | NPD2509 | Approved |
0.7154 | Intermediate Similarity | NPD4667 | Clinical (unspecified phase) |
0.7143 | Intermediate Similarity | NPD1955 | Discontinued |
0.7133 | Intermediate Similarity | NPD7690 | Clinical (unspecified phase) |
0.7097 | Intermediate Similarity | NPD2121 | Clinical (unspecified phase) |
0.7097 | Intermediate Similarity | NPD7924 | Phase 2 |
0.7097 | Intermediate Similarity | NPD7925 | Phase 2 |
0.7093 | Intermediate Similarity | NPD6160 | Clinical (unspecified phase) |
0.7091 | Intermediate Similarity | NPD3801 | Clinical (unspecified phase) |
0.7085 | Intermediate Similarity | NPD8421 | Discontinued |
0.7082 | Intermediate Similarity | NPD7180 | Phase 3 |
0.7082 | Intermediate Similarity | NPD5850 | Phase 3 |
0.7077 | Intermediate Similarity | NPD5640 | Discontinued |
0.7073 | Intermediate Similarity | NPD2778 | Approved |
0.707 | Intermediate Similarity | NPD5532 | Phase 2 |
0.7065 | Intermediate Similarity | NPD6531 | Approved |
0.7065 | Intermediate Similarity | NPD6530 | Approved |
0.7052 | Intermediate Similarity | NPD7022 | Phase 2 |
0.7048 | Intermediate Similarity | NPD4558 | Phase 2 |
0.7036 | Intermediate Similarity | NPD7470 | Discontinued |
0.7036 | Intermediate Similarity | NPD7393 | Clinical (unspecified phase) |
0.7027 | Intermediate Similarity | NPD8356 | Approved |
0.7007 | Intermediate Similarity | NPD8370 | Discontinued |
0.7007 | Intermediate Similarity | NPD4926 | Clinical (unspecified phase) |
0.7004 | Intermediate Similarity | NPD5632 | Approved |
0.6996 | Remote Similarity | NPD7589 | Clinical (unspecified phase) |
0.6985 | Remote Similarity | NPD8430 | Approved |
0.6985 | Remote Similarity | NPD7994 | Phase 2 |
0.6957 | Remote Similarity | NPD6961 | Discontinued |
0.6953 | Remote Similarity | NPD5417 | Clinical (unspecified phase) |
0.6947 | Remote Similarity | NPD8289 | Discontinued |
0.6932 | Remote Similarity | NPD4898 | Clinical (unspecified phase) |
0.6932 | Remote Similarity | NPD5479 | Discontinued |
0.6932 | Remote Similarity | NPD1659 | Phase 1 |
0.6931 | Remote Similarity | NPD8091 | Phase 3 |
0.6929 | Remote Similarity | NPD4454 | Phase 2 |
0.6926 | Remote Similarity | NPD5612 | Discontinued |
0.6926 | Remote Similarity | NPD6716 | Phase 1 |
0.692 | Remote Similarity | NPD7268 | Clinical (unspecified phase) |
0.6917 | Remote Similarity | NPD4373 | Phase 2 |
0.6914 | Remote Similarity | NPD7885 | Phase 2 |
0.6914 | Remote Similarity | NPD7886 | Phase 2 |
0.6898 | Remote Similarity | NPD8101 | Phase 3 |
0.6897 | Remote Similarity | NPD6824 | Clinical (unspecified phase) |
0.6889 | Remote Similarity | NPD6790 | Phase 1 |
0.6885 | Remote Similarity | NPD8479 | Phase 2 |
0.6884 | Remote Similarity | NPD6252 | Clinical (unspecified phase) |
0.6882 | Remote Similarity | NPD7708 | Approved |
0.688 | Remote Similarity | NPD7031 | Phase 1 |
0.6868 | Remote Similarity | NPD4894 | Discontinued |
0.6868 | Remote Similarity | NPD4952 | Phase 3 |
0.6854 | Remote Similarity | NPD6741 | Clinical (unspecified phase) |
0.6854 | Remote Similarity | NPD7558 | Phase 2 |
0.685 | Remote Similarity | NPD7467 | Discontinued |
0.6848 | Remote Similarity | NPD3794 | Approved |
0.6848 | Remote Similarity | NPD7859 | Phase 2 |
0.6848 | Remote Similarity | NPD3795 | Approved |
0.6844 | Remote Similarity | NPD7803 | Approved |
0.6842 | Remote Similarity | NPD1467 | Approved |
0.6842 | Remote Similarity | NPD1505 | Phase 2 |
0.6842 | Remote Similarity | NPD1466 | Phase 3 |
0.6842 | Remote Similarity | NPD1867 | Approved |
0.6842 | Remote Similarity | NPD7284 | Clinical (unspecified phase) |
0.684 | Remote Similarity | NPD484 | Approved |
0.6838 | Remote Similarity | NPD3507 | Phase 2 |
0.6836 | Remote Similarity | NPD5475 | Discontinued |
0.6836 | Remote Similarity | NPD6567 | Clinical (unspecified phase) |
0.6836 | Remote Similarity | NPD3809 | Discontinued |
0.6834 | Remote Similarity | NPD7823 | Clinical (unspecified phase) |
0.6831 | Remote Similarity | NPD8363 | Approved |
0.6831 | Remote Similarity | NPD8364 | Approved |
0.683 | Remote Similarity | NPD5559 | Phase 2 |
0.6828 | Remote Similarity | NPD8460 | Approved |
0.6828 | Remote Similarity | NPD8459 | Approved |
0.6827 | Remote Similarity | NPD772 | Phase 3 |
0.6825 | Remote Similarity | NPD6276 | Discontinued |
0.6823 | Remote Similarity | NPD2311 | Clinical (unspecified phase) |
0.6823 | Remote Similarity | NPD8463 | Approved |
0.6822 | Remote Similarity | NPD7538 | Clinical (unspecified phase) |
0.6821 | Remote Similarity | NPD5116 | Phase 1 |
0.6815 | Remote Similarity | NPD4394 | Clinical (unspecified phase) |
0.6809 | Remote Similarity | NPD5866 | Approved |
0.6809 | Remote Similarity | NPD7069 | Discontinued |
0.6806 | Remote Similarity | NPD8466 | Approved |
0.6806 | Remote Similarity | NPD8465 | Approved |
0.6806 | Remote Similarity | NPD8467 | Approved |
0.6805 | Remote Similarity | NPD6199 | Discontinued |
0.6801 | Remote Similarity | NPD1483 | Discontinued |
0.68 | Remote Similarity | NPD4369 | Phase 2 |
0.6798 | Remote Similarity | NPD3947 | Discontinued |
0.6792 | Remote Similarity | NPD4845 | Discontinued |
0.6788 | Remote Similarity | NPD8100 | Phase 3 |
0.6786 | Remote Similarity | NPD7955 | Approved |
0.6786 | Remote Similarity | NPD7956 | Approved |
0.6783 | Remote Similarity | NPD8365 | Clinical (unspecified phase) |
0.6775 | Remote Similarity | NPD3986 | Discontinued |
0.6765 | Remote Similarity | NPD7417 | Discontinued |
0.676 | Remote Similarity | NPD5018 | Phase 3 |
0.6754 | Remote Similarity | NPD4885 | Approved |
0.6749 | Remote Similarity | NPD6456 | Discontinued |
0.6747 | Remote Similarity | NPD8429 | Approved |
0.6747 | Remote Similarity | NPD8428 | Approved |
0.6747 | Remote Similarity | NPD8427 | Approved |
0.6743 | Remote Similarity | NPD7395 | Discontinued |
0.6742 | Remote Similarity | NPD5801 | Clinical (unspecified phase) |
0.674 | Remote Similarity | NPD3322 | Phase 1 |
0.6734 | Remote Similarity | NPD1038 | Approved |
0.6732 | Remote Similarity | NPD4033 | Approved |
0.6732 | Remote Similarity | NPD4038 | Approved |
0.6732 | Remote Similarity | NPD31 | Approved |
0.6732 | Remote Similarity | NPD4122 | Approved |
0.6732 | Remote Similarity | NPD4036 | Approved |
0.6732 | Remote Similarity | NPD4034 | Approved |
0.6732 | Remote Similarity | NPD4037 | Approved |
0.6732 | Remote Similarity | NPD4039 | Approved |
0.6732 | Remote Similarity | NPD32 | Approved |
0.6732 | Remote Similarity | NPD4035 | Approved |
0.6729 | Remote Similarity | NPD5040 | Clinical (unspecified phase) |
0.6729 | Remote Similarity | NPD4086 | Phase 1 |
0.6725 | Remote Similarity | NPD5922 | Phase 3 |
0.6712 | Remote Similarity | NPD8425 | Approved |
0.6712 | Remote Similarity | NPD8426 | Approved |
0.6705 | Remote Similarity | NPD3326 | Clinical (unspecified phase) |
0.6703 | Remote Similarity | NPD8358 | Approved |
0.6702 | Remote Similarity | NPD4442 | Phase 2 |
0.6691 | Remote Similarity | NPD7796 | Approved |
0.6691 | Remote Similarity | NPD7797 | Approved |
0.6679 | Remote Similarity | NPD5924 | Discontinued |
0.6679 | Remote Similarity | NPD8102 | Discontinued |
0.6679 | Remote Similarity | NPD2011 | Clinical (unspecified phase) |
0.6679 | Remote Similarity | NPD8405 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD5908 | Clinical (unspecified phase) |
0.6655 | Remote Similarity | NPD6495 | Clinical (unspecified phase) |
0.6654 | Remote Similarity | NPD4343 | Phase 1 |
0.6654 | Remote Similarity | NPD4344 | Clinical (unspecified phase) |
0.6654 | Remote Similarity | NPD3402 | Phase 1 |
0.6654 | Remote Similarity | NPD8372 | Clinical (unspecified phase) |
0.6653 | Remote Similarity | NPD5003 | Discontinued |
0.6644 | Remote Similarity | NPD7053 | Clinical (unspecified phase) |
0.6642 | Remote Similarity | NPD6209 | Approved |
0.6642 | Remote Similarity | NPD6964 | Approved |
0.6642 | Remote Similarity | NPD6963 | Approved |
0.6641 | Remote Similarity | NPD8326 | Phase 3 |
0.6641 | Remote Similarity | NPD5067 | Phase 2 |
0.6641 | Remote Similarity | NPD8327 | Clinical (unspecified phase) |
0.6641 | Remote Similarity | NPD4989 | Phase 2 |
0.6641 | Remote Similarity | NPD8325 | Phase 3 |
0.6641 | Remote Similarity | NPD5066 | Phase 2 |
0.6632 | Remote Similarity | NPD5459 | Phase 2 |
0.663 | Remote Similarity | NPD3962 | Phase 2 |
0.663 | Remote Similarity | NPD3959 | Phase 2 |
0.663 | Remote Similarity | NPD6263 | Clinical (unspecified phase) |
0.6629 | Remote Similarity | NPD3783 | Clinical (unspecified phase) |
0.6629 | Remote Similarity | NPD1996 | Discontinued |
0.6629 | Remote Similarity | NPD3280 | Approved |
0.662 | Remote Similarity | NPD7862 | Clinical (unspecified phase) |
0.6619 | Remote Similarity | NPD8247 | Approved |
0.6619 | Remote Similarity | NPD8246 | Approved |
0.6618 | Remote Similarity | NPD5469 | Phase 3 |
0.6616 | Remote Similarity | NPD7878 | Phase 2 |
0.6616 | Remote Similarity | NPD3354 | Phase 2 |
0.6615 | Remote Similarity | NPD8097 | Phase 3 |
0.6615 | Remote Similarity | NPD8096 | Phase 3 |
0.6614 | Remote Similarity | NPD5512 | Phase 3 |
0.6607 | Remote Similarity | NPD5857 | Phase 3 |
0.6605 | Remote Similarity | NPD4460 | Clinical (unspecified phase) |
0.6604 | Remote Similarity | NPD3259 | Approved |
0.6604 | Remote Similarity | NPD6298 | Discontinued |
0.6604 | Remote Similarity | NPD4923 | Phase 1 |
0.6603 | Remote Similarity | NPD8160 | Phase 2 |
0.6602 | Remote Similarity | NPD1166 | Clinical (unspecified phase) |
0.6601 | Remote Similarity | NPD3825 | Phase 3 |
Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.